Bayer says menopause drug succeeds in breast cancer study
The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...
Cutting Middle Management: Bayer's Costly Experiment One Year Later
In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.
Pharmabiz21h
Bayer’s subsidiary, Vividion acquires Tavros Therapeutics to expand functional genomics capabilities and boost drug discovery platform
San Diego, California Friday, January 10, 2025, 10:00 Hrs [IST] ...
Bayer: Sell And Be Done With It
Bayer's projected earnings decline and litigation pressures affect its outlook. Find out why BAYRY stock might face ...
ncbiotech.org1d
Durham’s Tavros Therapeutics sold to subsidiary of German giant Bayer AG
Durham-based Tavros Therapeutics, a precision oncology company spun out of Duke University, has been acquired by a subsidiary of global life sciences titan Bayer AG. Financial terms of the deal with ...
Bayer menopause drug reduces hot flashes in breast cancer group
Bayer AG reported positive results for elinzanetant in women with or at high risk of a type of breast cancer, broadening the ...
Bayer Aktiengesellschaft (ETR:BAYN) Shares Up 0.4% – Here’s Why
Bayer Aktiengesellschaft (ETR:BAYN – Get Free Report) shares were up 0.4% on Wednesday . The stock traded as high as €19.99 ($20.61) and last traded at €19.79 ($20.40). Approximately 3,072,022 shares ...
Bayer aims to expand presence in India with new therapies and strategic collaborations
Bayer's Global Capability Centre in Hyderabad contributes to R&D, data science, and AI-driven healthcare solutions, ...
Bernstein Sticks to Their Hold Rating for Bayer (0P6S)
Bernstein analyst Florent Cespedes maintained a Hold rating on Bayer (0P6S – Research Report) today and set a price target of €30.00. The ...
Daily2d
Bayer partner seeks approval for Darolutamide plus androgen deprivation therapy for metastatic hormone sensitive prostate cancer
Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...
Pharmaceutical Technology11d
Rogaratinib by Bayer for Solid Tumor: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...